BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27625094)

  • 1. HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b.
    Ma H; Yang RF; Li XH; Jin Q; Wei L
    Chin Med J (Engl); 2016 Sep; 129(18):2212-9. PubMed ID: 27625094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients.
    Ma H; Yang RF; Wei L
    J Gastroenterol Hepatol; 2010 Sep; 25(9):1498-506. PubMed ID: 20796146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China.
    Sun J; Ding H; Chen G; Wang G; Wei L; Zhang J; Xie Q; Wan M; Tang H; Chen S; Gao Z; Wang Y; Zhang D; Huang W; Sheng J; Ning Q; Yang D; Lu J; Pan C; Yang Y; Wang J; Sun C; Wang Q; Hou J
    BMC Gastroenterol; 2019 May; 19(1):65. PubMed ID: 31046700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Analysis of Polyethylene Glycol Interferon-α Treatment in 155 Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) Patients.
    Luo X; Yu JX; Xie L; Ma WJ; Wang LH
    Ann Hepatol; 2017 November-December,; 16(6):888-892. PubMed ID: 29055925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum hepatitis B virus RNA levels as a predictor of HBeAg seroconversion during treatment with peginterferon alfa-2a.
    Jia W; Zhu MQ; Qi X; Wang T; Wen X; Chen PD; Fan QQ; Zhang WH; Zhang JM
    Virol J; 2019 May; 16(1):61. PubMed ID: 31064399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
    Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapidly decreased HBV RNA predicts responses of pegylated interferons in HBeAg-positive patients: a longitudinal cohort study.
    Zhang M; Li G; Shang J; Pan C; Zhang M; Yin Z; Xie Q; Peng Y; Mao Q; Xiao X; Jiang Y; Luo K; Xu Y; Ding H; Fan W; Diego V; Pourkarim MR; De Clercq E; Wang G; Gong G
    Hepatol Int; 2020 Mar; 14(2):212-224. PubMed ID: 32100261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive role of early treatment dynamics of HBV RNA and HBcrAg for HBeAg seroconversion in children with chronic hepatitis B.
    Lai X; OuYang W; Li S; Qiu J; Zhang H; Jiang T; Qin X; Tang L; Gu Y; Yao Z; Peng S
    J Med Virol; 2024 May; 96(5):e29670. PubMed ID: 38773810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction model for sustained hepatitis B e antigen seroconversion to peginterferon alfa-2a in chronic hepatitis B.
    Zhu H; Wang C; Zhang Y; Wei S; Li X; Zhang Z
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1963-1970. PubMed ID: 27075693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. α-2-HS-glycoprotein is a potential marker predicting hepatitis B e antigen seroconversion in patients with chronic hepatitis B during treatment with pegylated interferon alpha-2b.
    Ma H; Wang J; Guo F; Wei L
    Sci China Life Sci; 2011 Jan; 54(1):39-47. PubMed ID: 21253869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
    Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H
    Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
    Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum HBV core-related antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients.
    Song G; Yang R; Rao H; Feng B; Ma H; Jin Q; Wei L
    J Med Virol; 2017 Mar; 89(3):463-468. PubMed ID: 27505145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Factors associated with HBeAg seroconversion in chronic hepatitis B patients treated with interferon alfa-2a].
    Li MH; Xie Y; Wu YZ; Xu DZ; Lu ZM; Hou JL; Jia JD; Wang YM; Zhang SL; Ren H; Chen XY
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jul; 15(7):481-4. PubMed ID: 17669233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.
    Wong VW; Wong GL; Yan KK; Chim AM; Chan HY; Tse CH; Choi PC; Chan AW; Sung JJ; Chan HL
    Hepatology; 2010 Jun; 51(6):1945-53. PubMed ID: 20209602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liver histopathological features influencing HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B responding to Peg-IFN treatment].
    Yan HD; Jiang FR; Zhu CL; Gao GS; Weng PJ; Hu AR; Xu CF; Hu YR; Sheng JF
    Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):340-4. PubMed ID: 24025133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.